Ikarian Capital, LLC Bellus Health Inc. Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $289,344 - $378,752	35,200 Added 4.14%	885,334 $7.28 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $1.51 Million - $2.02 Million	-168,193 Reduced 16.52%	850,134 $8.98 Million
Q2 2022 Aug 12, 2022	BUY	$6.46 - $10.02 $678,300 - $1.05 Million	105,000 Added 11.5%	1,018,327 $9.41 Million
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $4.8 Million - $6.9 Million	863,327 Added 1726.65%	913,327 $6.28 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $3.65 Million - $5.77 Million	-694,616 Reduced 93.29%	50,000 $402,000
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $718,008 - $1.77 Million	-265,929 Reduced 26.32%	744,616 $4.57 Million
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.61 $1.9 Million - $2.81 Million	610,545 Added 152.64%	1,010,545 $3.14 Million
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $908,999 - $1.37 Million	300,000 Added 300.0%	400,000 $1.54 Million
Q3 2020 Nov 16, 2020	BUY	$2.14 - $12.02 $214,000 - $1.2 Million	100,000 New	100,000 $227,000
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $565,842 - $710,489	-63,721 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$5.76 - $7.6 $367,032 - $484,279	63,721 New	63,721 $625,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.